-
VERAXA Biotech Announces Regulatory Progress with its BiTAC®-TCE Development Plan
ZURICH, SWITZERLAND – July 20, 2026 – VERAXA Biotech AG (NASDAQ: VRXA; “VERAXA), an emerging leader in designing novel cancer therapies, today announced that it has received Scientific Advice from the German regulatory authority, the Paul-Ehrlich-Institute (PEI), regarding the underlying biology and proposed non-clinical development plan for its most-advanced development program based on its proprietary…
-
Alvotech announces resubmission of U.S. Biologics License Applications for AVT05, a proposed biosimilar to Simponi® and Simponi Aria®, and AVT06, a proposed biosimilar to Eylea®
REYKJAVIK, Iceland, June 4, 2026 – Alvotech (NASDAQ: ALVO; ALVO-SDB), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced the resubmission to the U.S. Food and Drug Administration (FDA) of Biologics License Applications (BLAs) for AVT05, a proposed biosimilar to Simponi® and Simponi Aria® (golimumab), and AVT06,…
-
J-Star Holding Provides Additional Details on Baytown Economic Development Foundation LOI Supporting Proposed U.S. Solid-State Battery Manufacturing Facility
Formal LOI Details Site Selection Support, Infrastructure Requirements, 18-Month Site Availability Commitment, and Framework for Long-Term Facility Development June 01, 2026 11:50 ET | Source: J-Star Holding Co., Ltd TAICHUNG CITY, Taiwan, June 01, 2026 (GLOBE NEWSWIRE) — J-Star Holding Co., Ltd. (Nasdaq: YMAT) (“J-Star” or the “Company”), today provided additional details regarding the commitment…
Latest News
About the Author
We increase the awareness of millions of users through our news networks. We are one of the most trusted news networks in the world.
